Synchrony Financial (SYF)
| Market Cap | 23.37B -12.7% |
| Revenue (ttm) | 9.78B +1.4% |
| Net Income | 3.24B -6.8% |
| EPS | 9.54 +4.8% |
| Shares Out | 311.40M |
| PE Ratio | 7.87 |
| Forward PE | 7.48 |
| Dividend | $1.36 (1.81%) |
| Ex-Dividend Date | Nov 5, 2026 |
| Volume | 2,105,564 |
| Open | 75.47 |
| Previous Close | 74.83 |
| Day's Range | 74.46 - 75.78 |
| 52-Week Range | 63.08 - 88.77 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 87.54 (+16.63%) |
| Earnings Date | Oct 20, 2026 |
About SYF
Synchrony Financial, together with its subsidiaries, operates as a consumer financial services company in the United States. The company provides credit products, such as credit cards, commercial credit products, and consumer installment loans. It also offers private label credit cards, dual and general purpose co-branded cards, short- and long-term installment loans, and consumer banking products; and deposit products, including certificates of deposit, individual retirement accounts, money market accounts, savings accounts, and sweep and affi... [Read more]
Financial Performance
In 2025, Synchrony Financial's revenue was $9.76 billion, an increase of 3.88% compared to the previous year's $9.39 billion. Earnings were $3.47 billion, an increase of 1.23%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for SYF stock is "Buy." The 12-month stock price target is $87.54, which is an increase of 16.63% from the latest price.
News
CareCredit Introduces CareCredit Pay Later, Offering Consumers Another Way to Plan and Pay for Health and Wellness Care
CareCredit Pay Later is CareCredit's enhanced installment loan product that will be presented digitally with CareCredit's revolving credit card to give consumers additional payment options and simplif...
Synchrony price target raised to $77 from $74 at JPMorgan
JPMorgan raised the firm’s price target on Synchrony (SYF) to $77 from $74 and keeps a Neutral rating on the shares post the earnings report. The company’s credit outperformed with…
Synchrony downgraded to In Line from Outperform at Evercore ISI
As previously reported, Evercore ISI downgraded Synchrony (SYF) to In Line from Outperform with a price target of $78, down from $80. The firm expects potential earnings headwinds and macro…
Synchrony price target raised to $94 from $93 at Barclays
Barclays analyst Terry Ma raised the firm’s price target on Synchrony (SYF) to $94 from $93 and keeps an Overweight rating on the shares. The company’s loan growth momentum continued…
Synchrony downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Synchrony (SYF) to In Line from Outperform with a $78 price target
Synchrony Financial Profit Falls on Higher Costs but Credit Trends Improve
Synchrony posted a third-quarter profit of $892 million, or $2.68 a share, down from $1.1 billion, or $2.86 a share, a year earlier.
Synchrony Financial Earnings Call Transcript: Q3 2026
Q3 purchase volume reached nearly $50B, up 8%, while net earnings were $892M and credit metrics improved YoY. FY26 EPS is expected at ~$9.50; portfolio seasoning, investment costs and deposit competition remain key considerations.
Synchrony Financial Slides: Q3 2026
Synchrony Financial has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 20, 2026.
Synchrony Financial Earnings release: Q3 2026
Synchrony Financial released its Q3 2026 earnings on October 20, 2026, summarizing the period's financial results.
Synchrony Financial Quarterly report: Q3 2026
Synchrony Financial has published its Q3 2026 quarterly earnings report on October 20, 2026.
Synchrony reports Q3 EPS $2.68, consensus $2.40
Reports Q3 tangible book value per share $42.79. Reports Q3 CET1 capital ratio 12.9%. “Synchrony (SYF) delivered another strong performance in the third quarter, highlighted by broad-based purchase vo...
Synchrony Reports Third Quarter 2026 Results
Company Announces Quarterly Common Stock Dividend of $0.34 Per Share STAMFORD, Conn., Oct. 20, 2026 /PRNewswire/ -- Synchrony Financial (NYSE: SYF) today announced its third quarter 2026 results for ...
Weave announces live availability of integration with CareCredit
Weave (WEAV) announced the live availability of its integration with CareCredit, a leading patient financing solution from Synchrony (SYF). The integration gives front-office staff real-time visibilit...
Weave and CareCredit Go Live with Integration That Places Patient Financing Inside the Front-Office Workflow
LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient communications and payments platform purpose-built for healthcare practices, today announced the live availabi...
Synchrony price target lowered to $83 from $84 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Synchrony (SYF) to $83 from $84 and keeps an Equal Weight rating on the shares. The firm expects Q3 results from the…
Synchrony price target lowered to $74 from $78 at JPMorgan
JPMorgan lowered the firm’s price target on Synchrony (SYF) to $74 from $78 and keeps a Neutral rating on the shares. The firm adjusted targets in the consumer finance group…
Synchrony initiated with a Market Perform at BMO Capital
BMO Capital analyst Andrew Bauch initiated coverage of Synchrony (SYF) with a Market Perform rating and $81 price target The firm cites the company’s elevated payment rates, “muted” receivables growth...
Synchrony price target lowered to $93 from $94 at Seaport Research
Seaport Research lowered the firm’s price target on Synchrony (SYF) to $93 from $94 and keeps a Buy rating on the shares.
Synchrony price target lowered to $86 from $90 at TD Cowen
TD Cowen lowered the firm’s price target on Synchrony (SYF) to $86 from $90 and keeps a Buy rating on the shares. The firm adjusted targets in the consumer finance…
Synchrony price target lowered to $81 from $87 at UBS
UBS lowered the firm’s price target on Synchrony (SYF) to $81 from $87 and keeps a Neutral rating on the shares.
Synchrony price target lowered to $80 from $86 at Evercore ISI
Evercore ISI analyst John Pancari lowered the firm’s price target on Synchrony (SYF) to $80 from $86 and keeps an Outperform rating on the shares. The firm expects “relatively solid”…
CareCredit Partners with Vetspire to Modernize Veterinary Payments with AI-Enabled Practice Solutions
CareCredit's embedded financing, combined with Vetspire's AI-enabled practice technology, helps veterinary teams streamline operations, improve client engagement and support timely pet care. Key Highl...
Synchrony and Oxford Economics Find Trust Will Define the Future of AI Shopping
New research shows consumers are more willing to let AI make purchases when they have clear protection, transparency and control Key Highlights Security and transparency matter most: Keeping data sec...
Synchrony to Announce Third Quarter 2026 Financial Results on October 20, 2026
STAMFORD, Conn., Sept. 22, 2026 /PRNewswire/ -- Synchrony (NYSE: SYF) plans to report its third quarter 2026 results on Tuesday, October 20, 2026.
Intelibly announces strategic partnership with Synchrony
Intelibly announced a strategic partnership with Synchrony (SYF). Through this partnership, Synchrony’s CareCredit health and wellness credit card will be integrated into Intelibly’s platform. “Our pa...